The WHO criteria for diagnosing early primary myelofibrosis involve evaluating both major and minor diagnostic criteria. The input for this computation consists of selecting the applicable criteria from provided lists. 

Major criteria options:
- Megakaryocytic proliferation and atypia, without reticulin fibrosis greater than grade 1, accompanied by increased age-adjusted bone marrow cellularity, granulocytic proliferation, and often decreased erythropoiesis.
- Not meeting the WHO criteria for BCR-ABL1 chronic myeloid leukemia, polycythemia vera, essential thrombocythemia, myelodysplastic syndromes, or other myeloid neoplasms.
- Presence of JAK2, CALR, or MPL mutation; alternatively, in the absence of these mutations, the presence of another clonal marker or the absence of minor reactive bone marrow reticulin fibrosis.

Minor criteria include:
- Palpable splenomegaly.
- Anemia not attributed to a comorbid condition.
- White blood cell count equal to or greater than 11×10⁹/L.
- Lactate dehydrogenase level increased to above the upper normal limit of the institutional reference range.

For a diagnosis of early primary myelofibrosis, all three major criteria must be satisfied. In addition, at least one of the minor criteria must be present, which should be confirmed in two consecutive determinations. 

To interpret the results:
- If the selected criteria include all the major criteria (A, B, and C) and at least one minor criterion (D, E, F, or G), the output will indicate that the diagnostic criteria are met.
- If these conditions are not fully satisfied, the output will state that the diagnostic criteria are not met.

This approach ensures a structured and comprehensive assessment of early primary myelofibrosis, guiding clinicians based on standardized criteria and facilitating accurate diagnosis when the necessary conditions are fulfilled.

The World Health Organization (WHO) criteria for early primary myelofibrosis is a diagnostic tool designed to identify patients with this specific hematological disorder at an early stage. The primary utility of this tool is to facilitate early diagnosis and intervention, potentially improving patient outcomes.

The criteria consist of both major and minor components. The major criteria include megakaryocytic proliferation and atypia without significant reticulin fibrosis, absence of other specific myeloid neoplasms according to WHO criteria, and the presence of specific genetic mutations or other clonal markers. The minor criteria, which must be confirmed in two consecutive determinations, include palpable splenomegacy, anemia not attributable to a comorbid condition, elevated white blood cell count, and increased lactate dehydrogenase levels.

The diagnostic criteria are met if all major criteria (megakaryocytic proliferation and atypia, absence of other myeloid neoplasms, and presence of specific genetic mutations or clonal markers) are present, along with at least one of the minor criteria (palpable splenomegaly, anemia, elevated white blood cell count, or increased lactate dehydrogenase levels). If these conditions are not met, the diagnostic criteria for early primary myelofibrosis according to the WHO are not fulfilled.

WHO criteria for early primary myelofibrosis